Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Vorbeck

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
British Journal of Cancer|August 17, 2000
Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphomaM Raderer, F Vorbeck, M Formanek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 1998
Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinomaM Leimer, A Kurtaran, P Smith-Jones, et al.
Journal of the National Cancer Institute|April 28, 1999
Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue typeM Raderer, J Valencak, F Pfeffel, et al.
The American Journal of Gastroenterology|February 6, 1999
Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotideM Raderer, M H Hejna, A Kurtaran, et al.
Gynecologic Oncology|June 1, 1994
Prognostic factors in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube CarcinomaA C Rosen, A Reiner, M Klein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 23, 1998
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancerM Raderer, A Kurtaran, Q Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998M Raderer, A Kurtaran, M Leimer, et al.
British Journal of Cancer|February 23, 1999
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo resultsM Raderer, G Hamilton, A Kurtaran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patientsI Virgolini, I Szilvasi, A Kurtaran, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
British Journal of Cancer|August 17, 2000
Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphomaM Raderer, F Vorbeck, M Formanek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 1998
Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinomaM Leimer, A Kurtaran, P Smith-Jones, et al.
Journal of the National Cancer Institute|April 28, 1999
Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue typeM Raderer, J Valencak, F Pfeffel, et al.
The American Journal of Gastroenterology|February 6, 1999
Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotideM Raderer, M H Hejna, A Kurtaran, et al.
Gynecologic Oncology|June 1, 1994
Prognostic factors in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube CarcinomaA C Rosen, A Reiner, M Klein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 23, 1998
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancerM Raderer, A Kurtaran, Q Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998M Raderer, A Kurtaran, M Leimer, et al.
British Journal of Cancer|February 23, 1999
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo resultsM Raderer, G Hamilton, A Kurtaran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patientsI Virgolini, I Szilvasi, A Kurtaran, et al.
Pageof 3